

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

**POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON 1 JUNE 2020**

At the annual general meeting (the “AGM”) of Genscript Biotech Corporation (the “Company”) held on 1 June 2020, all the proposed resolutions put to the vote have been taken by way of poll, as set out in the revised notice of AGM dated 26 April 2020.

As at the date of the AGM, the total number of issued shares of the Company was 1,895,935,194 shares of US\$0.001 each, which was the total number of shares entitling the holder to attend and vote on the resolutions at the AGM. There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) nor any shares of holders required under the Listing Rules to abstain from voting at the AGM.

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “Directors”) and auditor of the Company for the year ended 31 December 2019.	1,170,417,963 (100%)	0 (0%)

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
2.	(A) (i) To re-elect Dr. Wang Luquan as non-executive Director.	1,165,210,484 (99.547243%)	5,299,566 (0.452757%)
	(ii) To re-elect Mr. Pan Yuexin as non-executive Director.	1,165,145,183 (99.539793%)	5,386,867 (0.460207%)
	(iii) To re-elect Mr. Dai Zumian as independent non-executive Director.	1,165,250,445 (99.550657%)	5,259,605 (0.449343%)
	(B) To authorize the board of Directors (the “ Board ”) to fix remuneration of the Directors.	1,170,343,700 (99.989034%)	128,350 (0.010966%)
3.	To re-appoint Ernst & Young, Certified Public Accountants, as the auditor of the Company and authorize the Board to fix remuneration of auditor.	1,170,510,050 (100%)	0 (0%)
4.	(A) To give a general and unconditional mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the number of issued shares of the Company.	1,023,002,323 (87.400833%)	147,469,727 (12.599167%)
	(B) To give a general and unconditional mandate to the Directors to repurchase shares not exceeding 10% of the number of issued shares of the Company.	1,170,233,650 (99.979632%)	238,400 (0.020368%)
	(C) To extend the authority given to the Directors pursuant to the ordinary resolution No. 4(A) to issue shares by adding the number of shares repurchased under the ordinary resolution No. 4(B).	1,023,026,323 (87.400046%)	147,483,727 (12.599954%)

As more than 50% of votes were casted in favour of each of the above ordinary resolutions numbered 1 to 4, all of the above ordinary resolutions were approved by the shareholders of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 1 June 2020

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* For identification purposes only